Clinical trials: Patients With Cancer
Metastatic Colorectal Cancer
A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic).
The purpose of this study is to collect additional safety and efficacy data during treatment with trifluridine / tipiracil in patients with a pretreated metastatic colorectal cancer (mCRC).
- Trial name
- PRECONNECT (NCT03306394)
- Testing
- Trifluridine/Tipiracil hydrochloride (S95005)
- Where
- 99 sites in Australia, Belgium and 14 more
- Volunteers
- 907 people
- Sponsor
- Institut de Recherches Internationales Servier
Colo-rectal Cancer
The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts
This is an open label, multicenter, randomized study in Chinese patients with RAS and BRAF wild-type mCRC. Participants were randomly assigned to cetuximab + FOLFOX (group A) and cetuximab + modified XELOX[mXELOX] (group B).
- Trial name
- NCT05074966
- Testing
- Experimental: mXELOX plus cetuximab, Active Comparator: FOLFOX plus cetuximab
- Where
- China
- Volunteers
- 314 people
- Sponsor
- Chinese Academy of Medical Sciences
Neoplasms, NUT Carcinoma
BI 894999 First in Human Dose Finding Study in Advanced Malignancies
This study is open to adults with different types of advanced cancer (solid tumours). The study is also open to patients with diffuse large B-cell lymphoma in whom previous treatment was not successful.
- Trial name
- NCT02516553
- Testing
- BI 894999
- Where
- 16 sites in United States, Belgium and 4 more
- Volunteers
- 174 people
- Sponsor
- Boehringer Ingelheim
Cervical Intraepithelial Neoplasia
Safety Study to Test the Safety of HspE7 and Poly-ICLC Given in Patients With Cervical Intraepithelial Neoplasia
The purpose of this study is to determine the safety and tolerability of HspE7 and Poly-ICLC when given together
- Trial name
- NCT00493545
- Testing
- HspE7 and Poly-ICLC
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Nventa Biopharmaceuticals Corporation
Breast Cancer
PS-341 in Treating Women With Metastatic Breast Cancer
RATIONALE: PS-341 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to study the effectiveness of PS-341 in treating women who have metastatic breast cancer.
- Trial name
- NCT00028639
- Testing
- bortezomib
- Where
- United States
- Sponsor
- Northwestern University
Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v6 and v7
Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer
This phase I/II trial is studying the side effects of giving paclitaxel together with radiation therapy with or without trastuzumab and to see how well it works to kill any remaining tumor cells in patients who have undergone…
- Conditions
- Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v6 and v7, Stage II Bladder Cancer AJCC v6 and v7, Stage III Bladder Cancer AJCC v6 and v7
- Trial name
- NCT00238420
- Testing
- Paclitaxel, Radiation Therapy, Trastuzumab
- Where
- 184 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
This study is being done to evaluate the safety, tolerability and effectiveness of Oral CG-806 for the treatment of patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas…
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma
- Trial name
- NCT03893682
- Testing
- CG-806
- Where
- 30 sites in United States
- Volunteers
- 36 people
- Sponsor
- Aptose Biosciences Inc.
Metastatic Endometrial Carcinoma, Recurrent Endometrial Adenocarcinoma
VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer
This phase I trial studies the side effects and best dose of vesicular stomatitis virus-human interferon beta-sodium iodide symporter (VSV-hIFNbeta-NIS) with or without ruxolitinib phosphate in treating patients with stage IV…
- Conditions
- Metastatic Endometrial Carcinoma, Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma
- Trial name
- NCT03120624
- Testing
- Biopsy, Computed Tomography, Fluorine F 18 Tetrafluoroborate
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Mayo Clinic
Hepatocellular Carcinoma
Yttrium-90 Radioembolization With Glass Microspheres (TheraSphere) for Patients With Hepatocellular Carcinoma
This is a prospective pilot study that will document the clinical experience of 30 patients with unresectable hepatocellular carcinoma undergoing liver-directed therapy with Yttrium-90 glass microspheres (TheraSphere®).
- Trial name
- NCT01290523
- Testing
- Selective internal radiation therapy of the liver with Yttrium-90 glass microspheres (TheraSphere)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of California, San Francisco
Carcinoma, Hepatocellular, Alcoholic Cirrhosis
Indocyanine Green and Portal Pressure in Viral and Alcoholic Cirrhotic Patients With Hepatocarcinoma
The aim of the investigators' study is to elucidate the relationship between a functional liver test (e.g., ICG) and the PREOPERATIVE value of portal hypertension in the patients with impaired liver function from alcoholic and…
- Conditions
- Carcinoma, Hepatocellular, Alcoholic Cirrhosis, Viral Cirrhosis, Postoperative Hepatic Failure
- Trial name
- NCT00827723
- Where
- Switzerland
- Volunteers
- 60 people
- Sponsor
- University of Lausanne Hospitals
Multiple Myeloma
VitD3 Supplementation in Patients With Multiple Myeloma
The goal of this clinical trial is to evaluate post-transplant immune reconstitution and lymphocyte recovery as well as the 3-year progression-free survival of patients with multiple myeloma in two treatment arms.
- Trial name
- NCT05846880
- Testing
- Lenalidomide, Maintenance Vitamin D, No maintenance Vitamin D
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Amany Keruakous, MD, MS.
Lung Cancer
Training Effects Following Resection Surgery in Patients With Lung Cancer
The purpose of this study is to determine the potential benefits resulting from a specific training on exercise tolerance and muscle function at the medium and long-time, as well as study its effects on plasmatic mediators…
- Trial name
- EMITOR (NCT01771796)
- Testing
- Aerobic and muscle resistance training
- Where
- 2 sites in Spain
- Volunteers
- 48 people
- Sponsor
- Parc de Salut Mar
Relapsed/Refractory Multiple Myeloma
Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of bispecific BCMA-GPRC5D CAR-T cells in patients with relapsed or refractory multiple myeloma who received three or more lines of therapy.
- Trial name
- NCT06515262
- Testing
- Anti-BCMA-GPRC5D CAR-T cells infusion
- Where
- China
- Volunteers
- 10 people
- Sponsor
- 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Cancer, Thrombosis
Efficacy & Safety of Prophylaxis With Bemiparin in Cancer Patients With a Central Venous Catheter (BECAT)
The purpose of this study is to evaluate the efficacy and safety of the subcutaneous administration for 45 days of Bemiparin (3,500 UI/day) in cancer patients with a CVC, to prevent CVC-related deep venous thrombosis (CVC-DVT)
- Trial name
- NCT00311896
- Testing
- Bemiparin
- Where
- 19 sites in Romania, Spain
- Volunteers
- 402 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Bone Metastases, Unspecified Adult Solid Tumor, Protocol Specific
Hydroxychloroquine in Treating Patients With Solid Tumors Undergoing Radiation Therapy for Bone Metastases
This phase I trial studies the side effects and best dose of hydroxychloroquine in treating patients with solid tumors undergoing radiation therapy for bone metastases.
- Trial name
- NCT01417403
- Testing
- hydroxychloroquine, radiation therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Virginia Commonwealth University
Breast Cancer
Cisplatin + RT for Triple Negative Breast Cancer
This is a Phase I dose escalation study of cisplatin and concurrent radiation in patients with ER negative, PR negative and HER2 negative breast cancer who have undergone breast-conserving surgery or mastectomy.
- Trial name
- NCT01674842
- Testing
- Radiation Therapy, Cisplatin
- Where
- 5 sites in United States
- Volunteers
- 55 people
- Sponsor
- Dana-Farber Cancer Institute
Lung Cancer
Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00113386
- Testing
- filgrastim, pegfilgrastim, cisplatin
- Where
- 76 sites in United States
- Volunteers
- 19 people
- Sponsor
- Radiation Therapy Oncology Group
Head and Neck Cancer Patients Treated With Radiotherapy
Effect of Radiation Therapy Among Head and Neck Cancer Patients on the Inner Ear Function
Aims: 1. To evaluate the effects of radiation therapy on the inner ear, among patients treated with radiation therapy for head and neck cancers using a wide battery of tests (Audiometry and tympanometry, vHIT, VEMP, ENG) ; 2.
- Trial name
- NCT04214769
- Testing
- Audiometry and tympanometry, vHIT, VEMP, ENG
- Volunteers
- 17 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Head and Neck Squamous Cell Carcinoma
A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer
It's a prospective, open-label, single arm, nonrandomized study of PEP503 in head and neck squamous cell carcinoma (HNSCC) patients.
- Trial name
- NCT02901483
- Testing
- PEP503, Cisplatin, Radiotherapy
- Where
- Taiwan
- Volunteers
- 12 people
- Sponsor
- PharmaEngine
Pancreatic Cancer, Pancreatic Adenocarcinoma
MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer
Objectives: Primary Objectives: Phase I: Determine the maximal tolerated dose (MTD) of MK-0646 in combination with gemcitabine or gemcitabine plus erlotinib and recommended phase II dose.
- Trial name
- NCT00769483
- Testing
- MK-0646, Gemcitabine, Erlotinib
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.